Immunotherapy: Does adjuvant ipilimumab have little adverse effect on quality of life?
Name:
nr Comment Nature Reviews 10th ...
Size:
286.4Kb
Format:
PDF
Description:
Author's manuscript
Affiliation
University of Manchester and Christie NHS Foundation Trust, Wilmslow Road, Manchester M20 4BX, UKIssue Date
2017-04-25
Metadata
Show full item recordCitation
Immunotherapy: Does adjuvant ipilimumab have little adverse effect on quality of life? 2017 Nat Rev Clin OncolJournal
Nature Reviews. Clinical OncologyDOI
10.1038/nrclinonc.2017.60PubMed ID
28440331Type
ArticleLanguage
enISSN
1759-4782ae974a485f413a2113503eed53cd6c53
10.1038/nrclinonc.2017.60
Scopus Count
Collections
Related articles
- Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.
- Authors: Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, Lebbé C, Ferraresi V, Smylie M, Weber JS, Maio M, Konto C, Hoos A, de Pril V, Gurunath RK, de Schaetzen G, Suciu S, Testori A
- Issue date: 2015 May
- Treatment of advanced melanoma with laser immunotherapy and ipilimumab.
- Authors: Naylor MF, Zhou F, Geister BV, Nordquist RE, Li X, Chen WR
- Issue date: 2017 May
- Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.
- Authors: Hodi FS, Chesney J, Pavlick AC, Robert C, Grossmann KF, McDermott DF, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen M, Ernstoff MS, Minor DR, Salama AK, Taylor MH, Ott PA, Horak C, Gagnier P, Jiang J, Wolchok JD, Postow MA
- Issue date: 2016 Nov
- Combined low-dose ipilimumab and pembrolizumab after sequential ipilimumab and pembrolizumab failure in advanced melanoma.
- Authors: Kirchberger MC, Hauschild A, Schuler G, Heinzerling L
- Issue date: 2016 Sep
- Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial.
- Authors: Ascierto PA, Del Vecchio M, Robert C, Mackiewicz A, Chiarion-Sileni V, Arance A, Lebbé C, Bastholt L, Hamid O, Rutkowski P, McNeil C, Garbe C, Loquai C, Dreno B, Thomas L, Grob JJ, Liszkay G, Nyakas M, Gutzmer R, Pikiel J, Grange F, Hoeller C, Ferraresi V, Smylie M, Schadendorf D, Mortier L, Svane IM, Hennicken D, Qureshi A, Maio M
- Issue date: 2017 May